Minimal clinically important change on the unified Parkinson's disease rating scale-Reference-Cited by-同舟云学术

Minimal clinically important change on the unified Parkinson's disease rating scale

Published:2006 Issue:8 Volume:21 Page:1200-1207
ISSN:0885-3185
Container-title:Movement Disorders
language:en
Short-container-title:Mov Disord.

Author:

Schrag Anette,Sampaio Cristina,Counsell Nicholas,Poewe Werner

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Reference37 articles.

1. , members of UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. Florham Park, NJ: MacMillan Healthcare Information; 1987. p 153–163.

2. Patterns of Outcome Measurement in Parkinson’s Disease Clinical Trials

3. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6-month interim report of a 3-year study

4. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease

5. Bilateral Stimulation of the Subthalamic Nucleus in Parkinson’s Disease: Surgical Efficacy and Prediction of Outcome

Cited by 246 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Deep brain stimulation for Parkinson’s disease: systematic review with meta-analysis and trial sequential analysis;BMJ Medicine;2024-08

2. Linking Invasive and Noninvasive Brain Stimulation in Parkinson's Disease: A Randomized Trial;Movement Disorders;2024-07-25

3. The Feasibility and Efficacy of a Virtual Reality Tandem Cycling Program for Persons with Parkinson’s Disease and Their Care Partners;Neurology and Therapy;2024-06-15

4. The effects of myofascial release in combined with task-oriented circuit training on balance in people with Parkinson’s disease: a randomized pilot trial;Neurological Research;2024-05-31

5. Study protocol of the GRoningen early-PD Ambroxol treatment (GREAT) trial: a randomized, double-blind, placebo-controlled, single center trial with ambroxol in Parkinson patients with a GBA mutation;BMC Neurology;2024-05-01